Using Coenzyme Q10 to prevent kidney injury in heart patients during angiography
Possible Role of Coenzyme Q10 in Prevention of Contrast Induced Nephropathy in Patients With Acute Coronary Syndrome Undergoing Coronary Angiography With or Without Intervention.
This study is testing if taking Coenzyme Q10 can help protect the kidneys of heart patients during angiography to prevent kidney injury.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 250 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Ain Shams University Academic / other |
| Locations | 2 sites (Cairo and 1 other locations) |
| Trial ID | NCT06429345 on ClinicalTrials.gov |
What this trial studies
This study investigates the effect of Coenzyme Q10 supplementation on reducing the incidence of contrast-induced acute kidney injury in patients with acute coronary syndrome undergoing coronary angiography. Participants will be randomly assigned to receive either CoQ10 along with standard preventive measures or standard preventive measures alone. The goal is to determine if CoQ10 can effectively protect kidney function during this procedure.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with ST-elevation myocardial infarction, non ST-elevation myocardial infarction, or unstable angina.
Not a fit: Patients with renal transplants, those experiencing preoperative or intraoperative bleeding, or those on nephrotoxic medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this could significantly reduce the risk of kidney injury in heart patients undergoing angiography.
How similar studies have performed: Other studies have explored the protective effects of Coenzyme Q10, but this specific application in acute coronary syndrome patients undergoing angiography is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients who are 18 years or older. * ST-elevation myocardial infarction (STEMI). * Non ST-elevation myocardial infarction( NSTEMI). * Unstable Angina (UA) Exclusion Criteria: * Renal transplant patients. * Preoperative bleeding . * Intraoperative bleeding or hypotension. * Patients taking any nephrotoxic medications
Where this trial is running
Cairo and 1 other locations
- Ain Shams university hospitals — Cairo, Egypt (Recruiting)
- Ramy Mohamed Mostafa — Cairo, Egypt (Not_yet_recruiting)
Study contacts
- Principal investigator: RAMY Mohamed — Resident of cardiology department,Ain shams university
- Study coordinator: Ramy Mohamed, Resident
- Email: 96ramymohamed22@gmail.com
- Phone: 01002820102
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.